NCT02570074View on ClinicalTrials.gov

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy Subjects
Interventions
DRUG

Fosfomycin

Broad spectrum antibiotic

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Vance Fowler, M.D.

OTHER

NCT02570074 - PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults | Biotech Hunter | Biotech Hunter